Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AVX-001, a cytosolic phospholipase A2 (cPLA2) inhibitor, is used potentially for the treatment of psoriasis.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,670.00 | |
50 mg | 6-8 weeks | $ 2,180.00 | |
100 mg | 6-8 weeks | $ 2,800.00 |
Description | AVX-001, a cytosolic phospholipase A2 (cPLA2) inhibitor, is used potentially for the treatment of psoriasis. |
Synonyms | FP-025, AKH-217, AKH217, AVX001, FP025 |
Molecular Weight | 386.51 |
Formula | C21H29F3OS |
CAS No. | 300553-18-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
AVX-001 300553-18-8 FP-025 AKH-217 AVX 001 AKH217 FP 025 AVX001 AKH 217 FP025 inhibitor inhibit